Authors
Hu, Z., Majeski, H. E., Mestre-Farrera, A., Cai, S., Lalezarzadeh, A., Zhang, Y., Arimoto, K.-I., Zhang, D.-E., Piwnica-Worms, H., Fattet, L., Yang, J.
Abstract
Mechanical cues from the extracellular matrix (ECM) regulate various cellular processes. In breast cancer, increased tumor stiffness is associated with elevated metastasis risk and poor survival. We identify a unique role of the JAK family kinase TYK2 in suppressing breast cancer metastasis under low ECM stiffness. Genetic or pharmacological inhibition of TYK2 in mammary acini and patient-derived organoids leads to invasion at low ECM stiffness by promoting Epithelial-Mesenchymal Transition, which is independent of cytokine-induced JAK/STAT signaling. TYK2 blockade promotes metastasis in breast tumor cell- and patient-derived xenografts. TYK2 localizes at the plasma membrane via IFNAR1 association under low stiffness, but it becomes cytoplasmic and inactivated at high stiffness. Normal human breast epithelium displays membrane-localized TYK2, whereas invasive breast tumors exhibit cytoplasmic TYK2. These findings uncover a TYK2-dependent mechanism by which ECM rigidity suppresses breast cancer metastasis and underscore the need for vigilant breast cancer screening in patients receiving TYK2 inhibitors.
Preprint server:
bioRxiv
The authors list and abstract were imported from bioRxiv on 31 Oct 2025.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 48
- Comments 0